T. Fan

Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: A cross-sectional, observational study

BACKGROUND & AIMS The burden of ulcerative colitis (UC) in relation to disease severity is not well documented. This study quantitatively evaluated the relationship between disease activity and quality of life (QoL), as well as health care utilization, cost, and work-related impairment associated with UC in an Australian population. METHODS A cross-sectional, noninterventional, observational study was performed in patients with a wide range of disease severity recruited during routine specialist consultations. Evaluations included the Assessment of Quality of Life-8-dimension (AQoL-8D), EuroQol 5-dimension, 5-level (EQ-5D-5L), the disease-specific Inflammatory Bowel Disease Questionnaire (IBDQ), and the Work Productivity and Activity Impairment (WPAI) instrument. The 3-item Partial Mayo Score was used to assess disease severity. Health care resource utilization was assessed by chart review and patient questionnaires. RESULTS In 175 patients, mean (SD) AQoL-8D and EQ-5D-5L scores were greater for patients in remission (0.80 [0.19] and 0.81 [0.18], respectively) than for patients with active disease (0.70 [0.20] and 0.72 [0.19], respectively, both Ps<0.001). IBDQ correlated with both AQoL-8D (r=0.73; P<0.0001) and EQ-5D-5L (0.69; P<0.0001). Mean 3-month UC-related health care cost per patient was AUD

P618 The relationship between disease severity, quality of life and health care resource utilization among United Kingdom patients with ulcerative colitis

2914 (SD=

P450 Long-term impacts of colectomy surgery among ulcerative colitis patients study (LOCUS): the final analysis

3447 [mean for patients in remission=

THU0435 Treatment Persistence with Subcutaneous Biologic Therapies in Patients with Psoriatic Arthritis (PSA)

1970; mild disease=

Treatment Persistence With Subcutaneous Biologic Therapies in Patients With Psoriatic Arthritis (Psa)

3736; moderate/severe disease=

P246 Disease control and unmet needs among moderate to severe ulcerative colitis patients treated with conventional therapies in Europe: The UC CARES (Ulcerative Colitis condition, attitude, resources and educational study) study

4162]). Patients in remission had the least work and activity impairment. CONCLUSIONS More severe UC disease was associated with poorer QoL. Substantial health care utilization, costs, and work productivity impairments were found in this sample of patients with UC. Moreover, greater disease activity was associated with greater health care costs and impairment in work productivity and daily activities.

Disease status, patient quality of life and healthcare resource use for ulcerative colitis in the UK: an observational study

Conclusions: Urinary metabolic profiling has shown distinct differences in South Asian IBD patients and controls, as has been previously shown in Caucasian studies. However, no difference in urinary hippurate was found between South Asian Crohn’s disease and UC patients, contrary to findings in Caucasians. Nor could these groups be distinguished using multivariate analysis. Some changes in the discriminatory metabolites are similar to those in Caucasian IBD but some are different suggesting an effect of ethnicity on the metabolic profile, which will be further investigated.

AB1091 Treatment Persistence with Subcutaneous Biologic Therapies in Patients with Rheumatoid Arthritis

to steroid therapy, although several serious side-effects may limit the use of the drug. Cyclosporine has been reported to increase the total cholesterol level; however the change in the serum cholesterol levels before and after cyclosporine therapy has not been examined in UC patients. The aim of this study was to compare the serum cholesterol levels before and after the cyclosporine therapy in patients with refractory UC and to examine the association between serum cholesterol level and other common side-effects. Methods: We retrospectively assessed the serum cholesterol levels of UC patients who had been treated with cyclosporine. Data of 72 patients (39 female, 33 male, mean age at diagnosis 31.7 years, mean disease duration: 13.5 years) were analyzed statistically. Results: The mean age of UC patients at the start of cyclosporine therapy was 40.3 years, and the mean disease duration at the beginning of the therapy was 8.6 years. The median duration of cyclosporine therapy was 9.6 months, and side effects developed in 52 patients. 65% of them developed increased cholesterol levels. The mean levels of serum cholesterol were 4.48, 6.1 and 5.08mmol/l at the beginning, during and at the end of the therapy. Elevated serum cholesterol levels were detected in 27% of the patients. Serum cholesterol level was significantly increased during and after stopping cyclosporine therapy compared the time before the use of the drug (p < 0.001, p < 0.004). However, cholesterol levels measured during the therapy was significantly higher compared to the time after stopping cyclosporine (p < 0.001). Significant association was found between the increased serum cholesterol levels and side effects developing during cyclosporine therapy. Conclusions: Our findings suggest that cyclosporine therapy may result in increased serum cholesterol levels even in longterm after stopping the therapy. Considering that cholesterol level were significantly more common in patients developing drug-related complications, routine measurement of serum cholesterol can increase the safety of the drug.

P283 Long-term impacts of colectomy surgery among ulcerative colitis patients study (LOCUS): A preliminary analysis

Background The treatment landscape of psoriatic arthritis has evolved in recent years, with the introduction of subcutaneous TNF-alpha blockers in the EU. These changes in the treatment landscape could affect how patients are managed with psoriatic arthritis. Objectives The objective of this study was to describe persistence with subcutaneous biologic over 12 months for newly treated PsA patients and evaluate the impact of prior DMARD use Methods This was a retrospective analysis using IMS Disease Analyzer-Germany, an electronic medical records database. Adult (≥18 years of age) PsA patients who initiated therapy with subcutaneous biologics between January 1, 2009 and June 30, 2012 were included in the analysis. The first subcutaneous biologic prescription date served as their index date. Continuous observation of at least 12 months pre- and post-index date was required. Patients who were prescribed any biologic during the pre-index period or diagnosed with rheumatoid arthritis, ankylosing spondylitis, Crohns disease, or ulcerative colitis during the study period were excluded from the study population. A chi-square test was used to measure differences between patients with and without use of pre-index DMARD. A multivariate logistic regression was created to assess the impact of DMARD use on persistence, controlling for baseline characteristics Results A total of 197 biologic-naïve PsA patients were selected. Of these, 89 were free of PsO. The mean (SD) age of the patients was 49 (11) years, with 50% being female. The majority of patients (61%) indexed on adalimumab, while the remainder indexed on etanercept (35%) and golimumab (4%). In the overall PsA population, the persistence rate with the index subcutaneous biologic was 54.3%, with similar results among those with and without DMARD uses (53% vs 56%, respectively). Multivariate analysis did not identify any significant predictors for persistence, including DMARD use (OR: 1.05; 95% CI: 0.53-2.07) and psoriasis (OR: 1.07; 95% CI: 0.56- 2.03 Conclusions More than half of the PsA patients were persistent with the index subcutaneous biologic over a 12-month period with similar persistence rates observed among those with and without psoriasis and DMARD use Disclosure of Interest R. Lyu Employee of: Merck, Q. Ding Employee of: Merck, M. Govoni Employee of: Merck, C. Makin: None declared, J. Korn: None declared, T. Fan Employee of: Merck, A. Ogbonnaya: None declared, C. Black Employee of: Merck, S. Kachroo Employee of: Merck

Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study.

Background • Psoriatic arthritis (PsA) is an inflammatory peripheral and/or axial arthritis associated with psoriasis, usually seronegative for rheumatoid factors1 • Patients with PsA also have debilitating skin disease, and nearly half may also have a spinal disease.2 PsA is estimated to affect 2.0% to 3.0% of the general population3 • To date, few studies have examined treatment persistence of subcutaneous biologics in a real-world setting in Europe, specifically in Germany Objectives • To examine persistence on therapy over 12 months for PsA patients who were newly treated with subcutaneous biologics • To assess if there are differences in treatment persistence between patients with and without prior DMARD experience